Cytokinetics Net Tangible Assets

Cytokinetics (CYTK) currently reports a net tangible assets of $-830M as of March 2026. That compares with $-270M in the prior-year period — down 210.3% year over year. Use the charts on this page to explore Cytokinetics's net tangible assets history and peer comparisons.

Cytokinetics's net tangible assets decreased from $-270M to $-830M — a 210.3% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cytokinetics reported $-830M in net tangible assets as of March 2026. That compares with $-270M in the prior-year period — down 210.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $-830M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cytokinetics, and consider following CYTK for alerts when major investors trade the stock.

Cytokinetics is classified in the Healthcare sector. On net tangible assets, it currently shows $-830M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CYTK with unrelated industries.